As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

11/20/14  Sanofi                            6-K        11/20/14    4:185K                                   Merrill Corp-MD/FA

Document/Exhibit                   Description                      Pages   Size 

 1: 6-K         Report of a Foreign Private Issuer                  HTML     24K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     26K 
 3: EX-99.2     Miscellaneous Exhibit                               HTML     25K 
 4: EX-99.3     Miscellaneous Exhibit                               HTML     60K 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

 

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

 

For the month of November 2014

 

Commission File Number: 001-31368

 

SANOFI

(Translation of registrant’s name into English)

 

54, rue La Boétie, 75008 Paris, FRANCE

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

 

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

 

If “Yes” marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):  82-

 

 

 

In November 2014, Sanofi issued the statements attached hereto as Exhibits 99.1 to 99.3 which are incorporated herein by reference.

 

Exhibit List

 

Exhibit No.		Description
Exhibit 99.1		Sanofi and Regeneron Announce that Dupilumab Has Received FDA Breakthrough Therapy Designation in Atopic Dermatitis
Exhibit 99.2		Sanofi Outlines Next Wave of Innovative Medicines and Vaccines
Exhibit 99.3		Sanofi and Regeneron Announce New Results from Six Phase 3 Trials Showing that Alirocumab Significantly Reduced LDL Cholesterol

 

2

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

Dated: November 20, 2014		SANOFI
	By		/S/    John Felitti
		Name:	John Felitti
		Title:	Associate Vice President,
			Corporate Law, Financial & Securities Law

 

3

 

Exhibit Index

 

Exhibit No.		Description
Exhibit 99.1		Sanofi and Regeneron Announce that Dupilumab Has Received FDA Breakthrough Therapy Designation in Atopic Dermatitis
Exhibit 99.2		Sanofi Outlines Next Wave of Innovative Medicines and Vaccines
Exhibit 99.3		Sanofi and Regeneron Announce New Results from Six Phase 3 Trials Showing that Alirocumab Significantly Reduced LDL Cholesterol

 

4